Urinary Exosomes as Potential Biomarkers for Diagnosis, Disease Activity Assessment, Treatment Monitoring, and Prognosis in Lupus Nephritis
Open Access
- 6 August 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 7051
Abstract
Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus and remains a major cause of chronic kidney damage and progression to end-stage renal disease. Although kidney biopsy is considered the diagnostic gold standard, its invasive nature, risk of complications, sampling limitations, and limited suitability for repeated monitoring highlight the need for reliable non-invasive biomarkers. Urinary exosomes have emerged as a promising source of renal molecular information because they are easily accessible and contain stable bioactive molecules, including microRNAs, transfer RNA-derived fragments, messenger RNAs, long non-coding RNAs, and proteins. This review summarizes available evidence on urinary exosomal biomarkers in lupus nephritis, with particular emphasis on their potential utility in diagnosis, assessment of disease activity, monitoring of treatment response, and prognosis. The literature search was conducted in PubMed and Embase using the keywords “lupus nephritis” and “urinary exosomes”. Studies were included if they investigated urinary exosomes in lupus nephritis and evaluated their relevance to disease diagnosis, activity, therapeutic response, histopathological findings, or renal outcomes. Among the analyzed biomarkers, urinary exosomal miR-146a appears to be the most consistently reported diagnostic marker, showing increased expression in active lupus nephritis and the ability to distinguish patients with renal involvement from those without nephritis. Other molecules, including selected miRNAs, tsRNAs, long RNAs, and proteins, have also shown potential clinical relevance, although their validation remains limited. Current evidence suggests that urinary exosomes may provide a non-invasive platform for improving the clinical assessment of lupus nephritis. However, most available studies are limited by small sample sizes, single-center designs, heterogeneous methodologies, and insufficient external validation. Further large-scale prospective studies are required to standardize exosome isolation and biomarker quantification and to determine whether urinary exosomal biomarker panels can complement kidney biopsy in clinical practice.Keywords
Funding Information
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (SUBZ.A500.25.019)
This publication has 77 references indexed in Scilit:
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus NephritisArthritis & Rheumatology, 2025
- Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells, Which Enhances Transforming Growth Factor β1 Activation and Promotes Tissue Fibrosis in Patients With Lupus NephritisArthritis & Rheumatology, 2024
- Systemic Lupus ErythematosusJAMA, 2024
- Exosomes: Membrane-associated proteins, challenges and perspectivesBiochemistry and Biophysics Reports, 2023
- Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysisRheumatology International, 2022
- Urinary exosomal miR-146a as a marker of albuminuria, activity changes and disease flares in lupus nephritisJournal Of Nephrology, 2020
- The potential role of tRNAs and small RNAs derived from tRNAs in the occurrence and development of systemic lupus erythematosusBiochemical and Biophysical Research Communications, 2020
- Regulation of JAK/STAT signal pathway by miR-21 in the pathogenesis of juvenile idiopathic arthritisWorld Journal of Pediatrics, 2019
- Urine exosomal ceruloplasmin: a potential early biomarker of underlying kidney diseaseClinical and Experimental Nephrology, 2019
- Selective Export into Extracellular Vesicles and Function of tRNA Fragments during T Cell ActivationCell Reports, 2018